Precision Medicine in Type 2 Diabetes: Using Individualized Prediction Models to Optimize Selection of Treatment
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Despite the known heterogeneity of type 2 diabetes and variable response to glucose lowering medications, current evidence on optimal treatment is predominantly based on average effects in clinical trials rather than individual-level characteristics. A precision medicine approach based on treatment response would aim to improve on this by identifying predictors of differential drug response for people based on their characteristics and then using this information to select optimal treatment. Recent research has demonstrated robust and clinically relevant differential drug response with all noninsulin treatments after metformin (sulfonylureas, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4] inhibitors, glucagon-like peptide 1 [GLP-1] receptor agonists, and sodium–glucose cotransporter 2 [SGLT2] inhibitors) using routinely available clinical features. This Perspective reviews this current evidence and discusses how differences in drug response could inform selection of optimal type 2 diabetes treatment in the near future. It presents a novel framework for developing and testing precision medicine–based strategies to optimize treatment, harnessing existing routine clinical and trial data sources. This framework was recently applied to demonstrate that “subtype” approaches, in which people are classified into subgroups based on features reflecting underlying pathophysiology, are likely to have less clinical utility compared with approaches that combine the same features as continuous measures in probabilistic “individualized prediction” models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Austin, P. C., & Stuart, E. A. (2015) · Statistics in Medicine · doi:10.1002/sim.6607 · Cited by 4,495
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 3×
“(2, 3) For the remaining majority, evidence of benefit beyond glucose-lowering with these drug classes has not been robustly demonstrated, and the optimal treatment pathway is not clear.(1) Evidence on the key considerations, notably glucose-lowering efficacy, tolerability, and sideeffects is mainly derived from avera…”
BackgroundInfluentialGlycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Data Resource Profile: Clinical Practice Research Datalink (CPRD)
Herrett, E., Gallagher, A. M., Bhaskaran, K., Forbes, H., Mathur, R., van Staa, T., & Smeeth, L. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv098 · Cited by 2,667 · cited 4×
“’s Clinical Practice Research Datalink (18), provide a rich source of “real-world” information on demographics, clinical features, diagnoses, laboratory tests, and prescriptions.”
BackgroundInfluentialAhlqvist, E., Storm, P., Käräjämäki, A., Martinell, M., Dorkhan, M., Carlsson, A., Vikman, P., Prasad, R. B., Aly, D. M., Almgren, P., et al. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30051-2 · Cited by 2,335
Mahajan, A., Taliun, D., Thurner, M., Robertson, N. R., Torres, J. M., Rayner, N. W., Payne, A. J., Steinthorsdottir, V., Scott, R. A., Grarup, N., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0241-6 · Cited by 1,744
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations
Pearson, E. R., Flechtner, I., Njølstad, P. R., Malecki, M. T., Flanagan, S. E., Larkin, B., Ashcroft, F. M., Klimes, I., Codner, E., Iotova, V., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061759 · Cited by 988 · cited 2×
“medicine approaches, ultimately prospective trials, as done in cancer and monogenic diabetes,(4, 56, 57) will likely be needed to demonstrate clinical utility.”
BackgroundGenetic cause of hyperglycaemia and response to treatment in diabetes
Pearson, E. R., Starkey, B. J., Powell, R. J., Gribble, F. M., Clark, P. M., & Hattersley, A. T. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14571-0 · Cited by 607
Zaharia, O. P., Strassburger, K., Strom, A., Bönhof, G. J., Karusheva, Y., Antoniou, S., Bódis, K., Markgraf, D. F., Burkart, V., Müssig, K., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30187-1 · Cited by 600 · cited 1×
“(34) Importantly, similar looking subgroups were identified when the analysis was repeated in multiple international population-based cohorts.(35, 36) Subgroups showed differences in outcomes in observational follow-up, although differential treatment response was not assessed.”
ResultUdler, M. S., Kim, J., von Grotthuss, M., Bonàs-Guarch, S., Cole, J. B., Chiou, J., ISGC, C. D. A. O. B. O. M. A. T., Boehnke, M., Laakso, M., Atzmon, G., et al. (2018) · PLOS Medicine · doi:10.1371/journal.pmed.1002654 · Cited by 542
The Predictive Approaches to Treatment effect Heterogeneity (PATH) statement
Kent, D. M., Paulus, J. K., van Klaveren, D., D'Agostino, R., Goodman, S., Hayward, R., Ioannidis, J. P. A., Patrick-Lake, B., Morton, S., Pencina, M., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m18-3667 · Cited by 469
Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials
Zhu, Z.-N., Jiang, Y.-F., & Ding, T. (2014) · Bone · doi:10.1016/j.bone.2014.08.010 · Cited by 253 · cited 1×
“Particular subgroups at higher risk of common treatment-specific side effects are already established for several drug classes; for example, the risk of fracture with TZD is limited mainly to females (49), and with SGLT2i females and those with a history of prior infection are at greatly increased risk of genital infe…”
BackgroundMastering variation: Variance components and personalised medicine
Senn, S. (2016) · Statistics in Medicine · doi:10.1002/sim.6739 · Cited by 205 · cited 1×
“through repeated crossover trial designs(11, 12)), but instead to identify people who are likely to have a greater relative benefit on one drug class over another.”
MethodStatistical pitfalls of personalized medicine
Senn, S. (2018) · Nature · doi:10.1038/d41586-018-07535-2 · Cited by 174 · cited 1×
“through repeated crossover trial designs(11, 12)), but instead to identify people who are likely to have a greater relative benefit on one drug class over another.”
MethodWallach, J. D., Sullivan, P. G., Trepanowski, J. F., Sainani, K. L., Steyerberg, E. W., & Ioannidis, J. P. A. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9125 · Cited by 148 · cited 1×
“This means very few “discovered” positive subgroups are subsequently replicated (14,15).”
BackgroundLynam, A., McDonald, T., Hill, A., Dennis, J., Oram, R., Pearson, E., Weedon, M., Hattersley, A., Owen, K., Shields, B., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-031586 · Cited by 72
A1C targets should be personalized to maximize benefits while limiting risks
Riddle, M. C., Gerstein, H. C., Holman, R. R., Inzucchi, S. E., Zinman, B., Zoungas, S., & Cefalu, W. T. (2018) · Diabetes Care · doi:10.2337/dci18-0018 · Cited by 54
Cited by
Stefan, N., & Schulze, M. B. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00086-4 · Cited by 215
A novel diabetes typology: towards precision diabetology from pathogenesis to treatment
Herder, C., & Roden, M. (2022) · Diabetologia · doi:10.1007/s00125-021-05625-x · Cited by 140
“An alternative strategy in precision diabetology may be based on statistical models using continuous risk factors [28, 58, 68].”
BackgroundArtificial intelligence for diabetes care: current and future prospects
Sheng, B., Pushpanathan, K., Guan, Z., Lim, Q. H., Lim, Z. W., Yew, S. M. E., Goh, J. H. L., Bee, Y. M., Sabanayagam, C., Sevdalis, N., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00154-2 · Cited by 106
Pigeyre, M., Hess, S., Gomez, M. F., Asplund, O., Groop, L., Paré, G., & Gerstein, H. (2022) · Diabetologia · doi:10.1007/s00125-021-05567-4 · Cited by 79
“Finally, our study was designed to assign individuals to one of the five mutually exclusive clusters, and did not have the purpose to compare the predictive performance of these models with probabilistic individualised prediction models combining the same clinical features as continuous measures [21].”
MethodDwibedi, C., Ekström, O., Brandt, J., Adiels, M., Franzén, S., Abrahamsson, B., & Rosengren, A. H. (2024) · Nature Metabolism · doi:10.1038/s42255-023-00943-3 · Cited by 40
Metadata
- Authors
- Dennis, J. M.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2020-08-25
- Volume
- 69
- Issue
- 10
- Pages
- 2075-2085
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W3080886764
- Cited by
- 119
- References
- 18
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.